Patient preferences toward herpes zoster vaccination among individuals aged 50 years or older in South Korea: Findings from a discrete choice experiment.

Sumitra Shantakumar¹, Eun Ju Choo², Raunak Parikh³, Taeyeon Kwon⁴, Hyungwoo Kim⁵, Lawrence Vandervoort⁶, Vince Grillo⁶, Jacob Lee⁷

¹GSK, Singapore, Singapore.

²Division of Infectious Disease, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea.

³GSK, Wavre, Belgium.

⁴GSK, Seoul, South Korea.

⁵GSK, Rockville, MD, USA.

⁶Cerner Enviza, an Oracle Company, Singapore, Singapore.

⁷Division of Infectious Disease, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.

PubMed PMC DOI PDF

Abstract

In South Korea, the increasing incidence of herpes zoster (HZ) and aging population warrant consideration of HZ vaccination for older adults. There is a need to understand the HZ vaccine-related preferences of adults aged ≥50 years and adult children (working or financially independent adults contributing to healthcare decision-making for their parents aged ≥50 years). A discrete choice experiment…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.